Status:
UNKNOWN
SMOFlipid and Incidence of BPD in Preterm Infants
Lead Sponsor:
University of Calgary
Conditions:
Very Low Birth Weight Infant
Bronchopulmonary Dysplasia
Eligibility:
All Genders
1-48 years
Phase:
NA
Brief Summary
Despite many advances in neonatal care in the recent years, bronchopulmonary dysplasia (BPD) continues to be the major cause of chronic lung morbidity in infants. The pathogenesis of BPD is multifacto...
Detailed Description
Intravenous lipid emulsions (IVLEs) is a core component of parenteral nutrition (PN) for providing calories and essential fatty acids. Until recently, Intralipid was the only available IVLE in North A...
Eligibility Criteria
Inclusion
- Preterm infants born \<30 weeks and admitted to NICU at Foothills Medical Centre in the first 24 hours of life.
- Anticipated duration of PN for \>7 days
Exclusion
- Infants with congenital anomalies
- Infants with suspected inborn errors of metabolism or family history of inborn error of metabolism
- Perinatal asphyxia
- Evidence of congenital infection
- Primary biliary atresia
Key Trial Info
Start Date :
December 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
384 Patients enrolled
Trial Details
Trial ID
NCT04078906
Start Date
December 16 2019
End Date
October 1 2024
Last Update
November 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foothills Medical Centre
Calgary, Alberta, Canada, T2N 2T9